Celularity (CELU) Amortization - Intangibles (2020 - 2025)
Celularity (CELU) posted quarterly Amortization - Intangibles of $368000.0 for Q1 2025, down 32.6% year-over-year from $546000.0 in Q1 2024, and down 2.13% quarter-over-quarter from $376000.0 in Q4 2024.
Celularity (CELU) Amortization - Intangibles (2020 - 2025) Analysis & Trends
Celularity (CELU) has reported Amortization - Intangibles for 6 consecutive years, with $368000.0 the latest figure, recorded in Q1 2025.
- In Q1 2025, Amortization - Intangibles fell 32.6% year-over-year to $368000.0; the TTM figure through Mar 2025 stood at $1.6 million (down 28.34% YoY), while the FY2025 annual figure was $1.5 million, down 14.83% from the prior year.
- Amortization - Intangibles fell to $368000.0 in Q1 2025 per CELU's latest filing, from $376000.0 in the prior quarter.
- Across five years, Amortization - Intangibles topped out at $553000.0 in Q3 2021 and bottomed at $368000.0 in Q1 2025.
- Historically, Amortization - Intangibles has averaged $511705.9 across 5 years, with a median of $546000.0 in 2021.
- Annual changes were most pronounced in 2024 — Amortization - Intangibles advanced 0.92% — and 2025, when it plunged 32.6%.
- Celularity's Amortization - Intangibles stood at $552000.0 in 2021, then advanced by 0.18% to $553000.0 in 2022, then changed by 0.0% to $553000.0 in 2023, then plunged by 32.01% to $376000.0 in 2024, then fell by 2.13% to $368000.0 in 2025.
- Business Quant data shows CELU's Amortization - Intangibles at $368000.0 in Q1 2025, $376000.0 in Q4 2024, and $375000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Celularity | 20.99 Mn | 14.82 Mn | -3.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 368,000.00 |
| Dec 31, 2024 | 376,000.00 |
| Sep 30, 2024 | 375,000.00 |
| Jun 30, 2024 | 456,000.00 |
| Mar 31, 2024 | 546,000.00 |
| Dec 31, 2023 | 553,000.00 |
| Sep 30, 2023 | 553,000.00 |
| Jun 30, 2023 | 546,000.00 |
| Mar 31, 2023 | 541,000.00 |
| Dec 31, 2022 | 553,000.00 |
| Sep 30, 2022 | 553,000.00 |
| Jun 30, 2022 | 546,000.00 |
| Mar 31, 2022 | 541,000.00 |
| Dec 31, 2021 | 552,000.00 |
| Sep 30, 2021 | 553,000.00 |
| Jun 30, 2021 | 546,000.00 |
| Mar 31, 2021 | 541,000.00 |
| Dec 31, 2020 | 551,000.00 |
| Sep 30, 2020 | 783,000.00 |